<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04674800</url>
  </required_header>
  <id_info>
    <org_study_id>AFIL-IJZ-3002</org_study_id>
    <nct_id>NCT04674800</nct_id>
  </id_info>
  <brief_title>Extension Study of MYL-1701P-3001 for Safety and Efficacy</brief_title>
  <official_title>A Multi Center, Extension Study to Evaluate the Safety and Efficacy of MYL-1701P in Subjects With Diabetic Macular Edema Completed MYL-1701P-3001 Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Momenta Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Study (AFIL-IJZ-3002) is designed to evaluate the safety, efficacy and immunogenicity of&#xD;
      MYL-1701P among a group of participants successfully completing MYL-1701P-3001 study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic retinopathy is an important cause of blindness worldwide. The International Diabetes&#xD;
      Federation estimates that 285 million people worldwide have diabetes mellitus and&#xD;
      approximately 7% of these individuals are affected by diabetic macular edema.&#xD;
&#xD;
      EYLEAÂ® (aflibercept) injection, an anti-Vascular Endothelial Growth Factor (VEGF) agent, has&#xD;
      been approved by the FDA and EMA for the treatment of Diabetic Macular Edema (DME).&#xD;
&#xD;
      Mylan Inc. and Momenta Pharmaceuticals, Inc. are developing MYL-1701P, a proposed biosimilar&#xD;
      to Eylea.&#xD;
&#xD;
      MYL-1701P-3001 study was designed to evaluate the efficacy, safety, pharmacokinetics, and&#xD;
      immunogenicity of MYL-1701P in the treatment of subjects with Diabetic Macular Edema (DME).&#xD;
      Eligible subjects from MYL-1701P-3001 study will be enrolled in the AFIL-IJZ-3002 study. All&#xD;
      enrolled subjects will receive three doses of MYL-1701P every eight weeks. Subjects will&#xD;
      attend the clinic visits for safety and efficacy assessments including BCVA, SD-OCT, complete&#xD;
      ophthalmological examinations during the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment emergent adverse events (TEAEs).</measure>
    <time_frame>Week 20</time_frame>
    <description>Number of participants with TEAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BCVA</measure>
    <time_frame>Weeks 8, 16 and 20</time_frame>
    <description>Best Corrected Visual Acuity (BCVA) will be assessed by Early Treatment Diabetic Retinopathy Letters (ETDRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CRT</measure>
    <time_frame>Weeks 8, 16 and 20</time_frame>
    <description>Central retinal thickness (CRT) will be evaluated using spectral-domain-optical coherence tomography (SD-OCT)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Single, test arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MYL-1701P- Subjects will receive 3 doses each of 2 mg at 8 weeks interval</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MYL-1701P, a proposed biosimilar to Eylea</intervention_name>
    <description>Open label and single arm</description>
    <arm_group_label>Single, test arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject participated in the MYL-1701P-3001 study&#xD;
&#xD;
          2. Subject requires treatment with intravitreal anti-VEGF therapy&#xD;
&#xD;
          3. Subject is able to understand and voluntarily provide written informed consent to&#xD;
             participate in the study.&#xD;
&#xD;
          4. If female of childbearing potential, the subject must have negative pregnancy tests&#xD;
             and should not be nursing or planning a pregnancy.&#xD;
&#xD;
          5. Subject is willing to comply with the study duration, study visits and study related&#xD;
             procedures.&#xD;
&#xD;
          6. If female, subject must be:&#xD;
&#xD;
               -  Surgically sterilized via hysterectomy, bilateral oophorectomy, or bilateral&#xD;
                  tubal ligation; or&#xD;
&#xD;
               -  Of childbearing potential and practicing an acceptable form of birth control&#xD;
&#xD;
               -  Of non-childbearing potential&#xD;
&#xD;
          7. If male, subject must be surgically or biologically sterile. If not sterile, the&#xD;
             subject must agree to use an acceptable form of birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with known hypersensitivity to aflibercept or any of the excipients&#xD;
&#xD;
          2. Subjects will be excluded if any of the following conditions are met in the study eye:&#xD;
&#xD;
               -  Subjects with active ocular inflammation.&#xD;
&#xD;
               -  Subjects with uncontrolled glaucoma&#xD;
&#xD;
               -  Surgery for glaucoma in the past or likely to be needed in the future.&#xD;
&#xD;
          3. Subjects with active or suspected ocular or periocular infection including but not&#xD;
             limited to infectious blepharitis, keratitis, scleritis, or conjunctivitis in either&#xD;
             eye.&#xD;
&#xD;
          4. Subjects who plan to participate in another clinical study while enrolled in this&#xD;
             study.&#xD;
&#xD;
          5. Subjects receiving treatment for a serious systemic infection.&#xD;
&#xD;
          6. Subjects with uncontrolled hypertension defined as systolic blood pressure &gt; 160 mm Hg&#xD;
             or diastolic blood pressure &gt; 95 mm Hg.&#xD;
&#xD;
          7. Subjects with a history of cerebrovascular accident or myocardial infarction within 6&#xD;
             months of enrollment.&#xD;
&#xD;
          8. Subjects with renal failure requiring dialysis or renal transplant.&#xD;
&#xD;
          9. Subjects with a history or presence of any clinically significant condition, that in&#xD;
             the opinion of the Investigator would jeopardize the safety of the subject or the&#xD;
             validity of the study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prasanna Ganapathi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mylan Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajesh Nachankar, Ph. D.</last_name>
    <phone>+91 80 66728952</phone>
    <email>Rajesh.nachankar@mylan.in</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nageswari Santosh, MSc</last_name>
    <phone>+91 80 66728248</phone>
    <email>nageswari.santosh1@mylan.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mylan Investigative site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mylan Investigative Site</name>
      <address>
        <city>Visakhapatnam</city>
        <state>Andhra Pradesh</state>
        <zip>530 040</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mylan Investigative Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mylan Investigative site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380016</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mylan Investigative site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 010</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mylan Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560094</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mylan Investigative Site</name>
      <address>
        <city>Bengaluru</city>
        <state>Karnataka</state>
        <zip>560037</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mylan Investigative Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharastra</state>
        <zip>400050</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mylan Investigative site</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Odisha</state>
        <zip>751024</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mylan Investigative Site</name>
      <address>
        <city>Chandigarh</city>
        <state>Punjab</state>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mylan Investigative site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302015</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mylan Investigative site</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <zip>625 020</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mylan Investigative site</name>
      <address>
        <city>Tirunelveli</city>
        <state>Tamilnadu</state>
        <zip>627002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mylan Investigative Site</name>
      <address>
        <city>Noida</city>
        <state>Uttar Pradesh</state>
        <zip>201301</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mylan Investigative site</name>
      <address>
        <city>New Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Macular Edema</keyword>
  <keyword>BCVA</keyword>
  <keyword>ETDRS Letters</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

